Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Investor Presentation (November 2023)
22 slides from Orchid Pharma's investor presentation, Nov 20, 2023
Slide 1: Intimation under Regulation 30 to stock exchanges
November 20, 2023 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers Bandra (E), Mumbai-400051, MH Dalal Street, Fort, Mumbai- 400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Intimation under Regulation 30 of the SEBI (Listing O
Slide 2: Marching Forwards
OrchidPharma?” — A Dhanuka Group Company —
Slide 3: Safe Harbor
SAFE HARBOR This presentation and the accompanying slides (the “Presentation”), which have been prepared by Orchid Pharma Ltd (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities,
Slide 4: Company overview
1 2 Company PIONEER IN CEPHALOSPORIN ANTIBIOTICS R&D Focused, Inventor of ABOUT DHANUKA GROUP ~ 3000 Crore diversified group. Interests in Crop Care and Pharma overview Enmetazobactam (Under Approval in US & Dhanuka Laboratories is the Pharma arm. EU) >25 years in Antibiotics space Acquired by Dhanu
Slide 5: History
History 1992 2005 2008 2009 2013 2015 - 2017 2019-20 2020-22 2022-23 2023-24 Orchid was First USFDA First ANDA First Para-IV Sells NPNC API Goes into CDR NCLT Approves Focus on Cost Changing Gears Growing from Formed Approval Approval filing for Pip-Taz business to and then Dhanuka’s plan. Reduction
Slide 6: Background and Pedigree
Background and Pedigree Dhanuka Laboratories Ltd. Pharmaceutical arm started in 1998 Leader in Cephalosporin Antibiotics Dhanuka Agritech Ltd. in Emerging markets JV with Otsuka - Japan, for Flagship of the Group founded in 1980. manufacturing advanced intermediates Listed on Stock Exchang
Slide 7: Key Rationale for Acquiring Orchid Pharma
Key Rationale Orchid World Leader in Cephalosporin Dhanuka Group Leader in Emerging Market space, for Acquiring Antibiotics focused on regulated markets with a strong R&D for new products Orchid Pharma Strengths Weaknesses Strengths Weaknesses Regulatory Approvals – High Cost Structure Cost Efficien
Slide 8: Current Corporate Structure
Current Dhanuka Group Corporate Structure 30% 70% 100% Dhanuka Laboratories Ltd. Public Dhanuka Agritech Ltd. (Unlisted) 72.4% 27.6% Orchid Pharma Public Ltd. & Others 100% 26% Orchid Orbion BioPharma Ltd. Pharmaceuticals Ltd. Other insignificant subsidiaries in US / EU are non operative and were li
Slide 9: About Antibiotics
About Antibiotics 20 November 2023
Slide 10: What are Antibiotics
What are Antibiotics Life Saving Drugs used to fight infections Before Penicillin by Alexander Fleming, average life expectancy was 40 years After Antibiotics, basics like child-birth, injuries, pneumonia and stomach infections were tackled which reduced preventable deaths Advanced procedures like o
Slide 11: Antibiotics Market
Antibiotics Market Global antibiotics market share, by drugs class Global Antibiotics Market in 2020 – USD 40 bn. Cephalosporins is the largest class with 30% share. Fastest growing at ~ 8% CAGR Cephalosporin Widest product range with more than 30 products approved worldwide Penicillin Cep
Slide 12: Why Orchid
Why Orchid 20 November 2023
Slide 13: Strong R&D capabilities
Strong R&D capabilities Orchid’s expertise All these combined, give us the Orchid pharma encompass the entire strength and ability to file First to File spectrum of Para 4 applications for US and other has been Pharmaceutical R&D regulatory markets. focused on R&D, 1. Synthesis R&D Non – Infringing
Slide 14: Widest range of Cephalosporins
Widest range of Ready to launch Cephalosporins Under development Generation Generation Generation Generation Generation Generation 1 2 3 4 5 6 Oral Cefadroxil Cefprozil Cefdinir Cefalexin Cefuroxime Cefditoren Cefradine Cefixime Cefpodoxime Ceftibuten Sterile Cefalonium Cefox
Slide 15: Leading - Integrated Cephalosporin API company
Leading - Integrated Vertically integrated with credentials in research, development, manufacturing and Cephalosporin API company marketing Integrated facilities from Intermediates to API spread across 60 acre, approved worldwide Presence across the antibiotic domains spread across oral and st
Slide 16: Unique Fact about Orchid's Facilities
Unique Fact USFDA APPROVED API SITES about Orchid’s Facilities ~200 Total API ~150 Total API Sterile Ceph Sterile Ceph Oral Ceph Oral Ceph 4 1 2 1 India China Orchid Estimates 20 November 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 15
Slide 17: Global Presence with a Wide Customer Base
Global Presence with a Wide Customer Base 20 November 2023 © Copyright OrchidPharma Ltd. All Rights Reserved 16
Slide 18: Competitive Advantage
Competitive Advantage Complexity Chemistry of Cephalosporins Sterile Manufacturing Orchid Legacy High Entry Barrier Cross Contamination Barrier High Capital Costs Cost Leadership Dhanuka Created Low Cost of Management Low Cost of Operations 20 November 2023 © Copyright OrchidPharma Ltd.
Slide 19: Progress So far
Progress So far 20 November 2023
Slide 20: Progress of Turnaround
Progress of Turnaround Before takeover After takeover Revenues EBITDA Term debt 103 427 666 600 53 55 348 50 560 508 34 450 382 296 148 82 -18 -25 0 FY19 FY20 FY21 FY22 FY23 HY-23 HY-24 FY19 FY20 FY21 FY22 FY23 HY23 HY24 FY20 FY21 FY22 FY23 HY24 20 November 2023 © Copyright OrchidPharma Ltd. All Rig
Slide 21: Efficiency and Productivity
Efficiency 60% 57% Efficiency and 50% Productivity 40% 36% 33% 32% 32% 30% 30% 27% • Operating 20% Leverage is clearly visible. 15% 14% 13% 13% 11% 11% 11% 11% 11% 10% 10% 10% 10% 10% 9% 9% 9% 8% • This is despite headwinds on energy prices. 0% Employees Power and Fuel Other Expenses Total Expenses
Slide 22: Thank You
OrchidPharma? A Dhanuka Group Company — Thank You
Orchid Pharma — Investor Presentation (November 2023) on 6ix